Integer (NYSE:ITGR) posted second-quarter results today that beat the overall consensus forecast on Wall Street.
The Plano, Texas-based medical device outsource manufacturer reported profits of $20.8 million, or 62¢ per share, on sales of $350 million for the three months ended July 1, for a bottom-line loss of 29.2% on sales growth of 12.2% compared with Q2 2021.
Adjusted to exclude one-time items, earnings per share were $1.04, 8¢ ahead of The Street, where analysts were looking for sales of $43.57 million.
“Integer delivered second quarter 2022 financial results consistent with our expectations, as sales grew 13% versus the first quarter 2022 and 12% versus prior year. Integer’s associates around the globe remain focused on delivering products for our customers and the patients they serve, while managing the challenges of the ongoing labor and supply chain dynamics,” President and CEO Joseph Dziedzic said in a news release.
Cardio and vascular …